Table 3.
Linear regression analysis for eGFR slope.
| Model | Variables | β-coefficient | 95% CI | P value |
|---|---|---|---|---|
| crude | Log EPO | 0.83 | 0.03–1.64 | 0.04 |
| 1 | Crude + age, sex, eGFR, log UACR, and hemoglobin | 0.86 | 0.01–1.71 | 0.05 |
| 2 | Model 1 + diabetic retinopathy, SBP, and HbA1c | 0.90 | 0.03–1.76 | 0.04 |
| 3 | Model 2 + ACE/ARB use and statin use | 0.89 | 0.01–1.77 | 0.05 |
| 4 | Model 3 + log FGF23 and 25D | 0.94 | 0.07–1.81 | 0.04 |
| 5 | Model 4 + log u-LFABP | 0.93 | 0.05–1.81 | 0.04 |
eGFR, estimated glomerular filtration rate; EPO, erythropoietin; CI, confidence interval; UACR, urine albumin-to-creatinine ratio; SBP, systolic blood pressure; HbA1c: hemoglobin A1c; ACE/ARB, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; FGF23, fibroblast growth factor 23; 25D, 25-hydroxyvitamin D; u-LFABP, urinary liver-type fatty acid-binding protein.